PURPOSE: Nanomedicines represent an alternative for the treatment of aggressive glioblastoma tumors. Behaviour of PLGA-nanoparticles (NPs) was here investigated as a function of their protein adsorption characteristics at the different biological interfaces they are expected to face in order to reach brain cancer cells. METHODS: NPs were studied for size, zeta potential, blood half-life, in vitro endocytic behavior and in vivo accumulation within healthy rat brain and brain tumors. RESULTS: While slightly modifying size (80 to 90 nm) and zeta potential (-44 to -32 mV) protein coating of PLGA-NPs by bovine serum albumin (BSA) or transferrin (Tf) greatly prolonged their blood half-life when intravenously injected in rats and mice. In contrast with THP-1 monocytes, differentiated THP-1 macrophages, F98 glioma cells and astrocytes internalized BSA- and Tf-NPs in vitro. Increase of Tf-NP uptake by F98 cells through caveolae- and clathrin-mediated pathways supports specific interaction between Tf and overexpressed Tf-receptor. Finally, in vivo targeting of healthy brain was found higher with Tf-NPs than with BSA-NPs while both NPs entered massively within brain-developed tumors. CONCLUSION: Taken together, those data evidence that Tf-NPs represent an interesting nanomedicine to deliver anticancer drugs to glioma cells through systemic or locoregional strategies at early and late tumor stages.
PURPOSE: Nanomedicines represent an alternative for the treatment of aggressive glioblastoma tumors. Behaviour of PLGA-nanoparticles (NPs) was here investigated as a function of their protein adsorption characteristics at the different biological interfaces they are expected to face in order to reach brain cancer cells. METHODS: NPs were studied for size, zeta potential, blood half-life, in vitro endocytic behavior and in vivo accumulation within healthy rat brain and brain tumors. RESULTS: While slightly modifying size (80 to 90 nm) and zeta potential (-44 to -32 mV) protein coating of PLGA-NPs by bovineserum albumin (BSA) or transferrin (Tf) greatly prolonged their blood half-life when intravenously injected in rats and mice. In contrast with THP-1 monocytes, differentiated THP-1 macrophages, F98 glioma cells and astrocytes internalized BSA- and Tf-NPs in vitro. Increase of Tf-NP uptake by F98 cells through caveolae- and clathrin-mediated pathways supports specific interaction between Tf and overexpressed Tf-receptor. Finally, in vivo targeting of healthy brain was found higher with Tf-NPs than with BSA-NPs while both NPs entered massively within brain-developed tumors. CONCLUSION: Taken together, those data evidence that Tf-NPs represent an interesting nanomedicine to deliver anticancer drugs to glioma cells through systemic or locoregional strategies at early and late tumor stages.
Authors: Stefan W Schneider; Thomas Ludwig; Lars Tatenhorst; Stephan Braune; Hans Oberleithner; Volker Senner; Werner Paulus Journal: Acta Neuropathol Date: 2004-01-17 Impact factor: 17.088
Authors: E Markoutsa; K Papadia; A D Giannou; M Spella; A Cagnotto; M Salmona; G T Stathopoulos; S G Antimisiaris Journal: Pharm Res Date: 2013-12-13 Impact factor: 4.200
Authors: David J Mc Carthy; Meenakshi Malhotra; Aoife M O'Mahony; John F Cryan; Caitriona M O'Driscoll Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2016-11-04
Authors: Michaela C Hohnholt; Mark Geppert; Eva M Luther; Charlotte Petters; Felix Bulcke; Ralf Dringen Journal: Neurochem Res Date: 2012-12-06 Impact factor: 3.996